Bristol Myers - Celgene CVRPreferred / convertible
13F holders, Q4 2025 (December 31)18holders −4
1new positions
4sold out
1famous investor
$0.07avg. 13F price*
At the end of Q4 2025, 18 institutions reported holding Bristol Myers - Celgene CVR in their 13F filings, down 4 from Q3 2025. 1 opened new positions and 4 sold out. The largest holders were Transcend Capital Advisors, LLC ($8K), DAVENPORT & Co LLC ($6K) and Bank of America Corp. ($4K). One famous investor held it Ken Griffin ( of Citadel Advisors's portfolio).
- Company
- Bristol Myers - Celgene CVR
- CUSIP
- 110122140
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $1K |
| Exits | 4 | $1.2M |
All 13F filers, Q3 2025 → Q4 2025: 16,079 shares bought and 864,221 shares sold, net −848,142 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 18 holders
| Transcend Capital Advisors, LLC | — | No change | 109,175 | $8K |
| DAVENPORT & Co LLC | — | No change | 83,970 | $6K |
| Bank of America Corp. | — | No change | 51,828 | $4K |
| Citadel Advisors | — | Reduce -14.6% | 27,970 | $2K |
| Purkiss Capital Advisors LLC | — | No change | 26,450 | $2K |
| Fifth Third Bancorp | — | No change | 20,000 | $1K |
| Private Advisor Group, LLC | — | No change | 15,000 | $1K |
| Virtu Financial LLC | — | New | 16,079 | $1K |
| Northwestern Mutual Wealth Management Co. | — | No change | 341 | $24 |
| Rothschild Investment LLC | — | No change | 166 | $12 |
| Morgan Stanley | — | No change | 119 | $9 |
| Oakworth Capital, Inc. | — | No change | 125 | $9 |
| JPMorgan Chase & Co. | — | No change | 23 | $2 |
| Wells Fargo & Company | — | No change | 28 | $2 |
| Atlantic Edge Private Wealth Management, LLC | — | No change | 16 | $2 |
| UBS Group AG | — | Reduce -99.9% | 10 | $1 |
| First Pacific Financial | — | No change | 6 | $1 |
| Royal Bank of Canada | — | No change | 2,475 | $0 |
"% of holder's portfolio" is BRISTOL MYERS - CELGENE CVR's weight in each manager's 13F, not the share of Bristol Myers - Celgene CVR the manager owns.